Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Formulation, Development, and In Vitro Evaluation of a CD22 Targeted Liposomal System Containing a Non-Cardiotoxic Anthracycline for B Cell Malignancies.

Mittal NK, Mandal B, Balabathula P, Setua S, Janagam DR, Lothstein L, Thoma LA, Wood GC.

Pharmaceutics. 2018 Apr 15;10(2). pii: E50. doi: 10.3390/pharmaceutics10020050.

2.
3.

The science and art of brief inpatient group therapy in the 21st century: commentary on Cook et al. and Ellis et al.

Lothstein LM.

Int J Group Psychother. 2014 Apr;64(2):228-44. doi: 10.1521/ijgp.2014.64.2.228. Review. No abstract available.

PMID:
24611703
4.

Group therapy for intimate partner violence (IPV).

Lothstein LM.

Int J Group Psychother. 2013 Jul;63(3):449-52. doi: 10.1521/ijgp.2013.63.3.449. No abstract available.

PMID:
23734925
5.

Group therapy for patients suffering from eating disorders.

Lothstein LM.

Int J Group Psychother. 2012 Jul;62(3):473-6. doi: 10.1521/ijgp.2012.62.3.473. No abstract available.

PMID:
22676792
6.

Protection from doxorubicin-induced cardiomyopathy using the modified anthracycline N-benzyladriamycin-14-valerate (AD 198).

Cai C, Lothstein L, Morrison RR, Hofmann PA.

J Pharmacol Exp Ther. 2010 Oct;335(1):223-30. doi: 10.1124/jpet.110.167965. Epub 2010 Jul 28.

7.

Involvement of PKC delta (PKCδ) in the resistance against different doxorubicin analogs.

Díaz Bessone MI, Berardi DE, Campodónico PB, Todaro LB, Lothstein L, Bal de Kier Joffé ED, Urtreger AJ.

Breast Cancer Res Treat. 2011 Apr;126(3):577-87. doi: 10.1007/s10549-010-0956-2. Epub 2010 May 30.

PMID:
20512658
8.

Interferon-resistant Daudi cell line with a Stat2 defect is resistant to apoptosis induced by chemotherapeutic agents.

Du Z, Fan M, Kim JG, Eckerle D, Lothstein L, Wei L, Pfeffer LM.

J Biol Chem. 2009 Oct 9;284(41):27808-15. doi: 10.1074/jbc.M109.028324. Epub 2009 Aug 17.

9.

N-Benzyladriamycin-14-valerate (AD 198): a non-cardiotoxic anthracycline that is cardioprotective through PKC-epsilon activation.

Hofmann PA, Israel M, Koseki Y, Laskin J, Gray J, Janik A, Sweatman TW, Lothstein L.

J Pharmacol Exp Ther. 2007 Nov;323(2):658-64. Epub 2007 Aug 10.

PMID:
17693586
10.

Phosphorylation of mitochondrial phospholipid scramblase 3 by protein kinase C-delta induces its activation and facilitates mitochondrial targeting of tBid.

He Y, Liu J, Grossman D, Durrant D, Sweatman T, Lothstein L, Epand RF, Epand RM, Lee RM.

J Cell Biochem. 2007 Aug 1;101(5):1210-21.

PMID:
17226776
11.
13.

N-benzyladriamycin-14-valerate (AD198) induces apoptosis through protein kinase C-delta-induced phosphorylation of phospholipid scramblase 3.

He Y, Liu J, Durrant D, Yang HS, Sweatman T, Lothstein L, Lee RM.

Cancer Res. 2005 Nov 1;65(21):10016-23.

14.

Circumvention of nuclear factor kappaB-induced chemoresistance by cytoplasmic-targeted anthracyclines.

Bilyeu JD, Panta GR, Cavin LG, Barrett CM, Turner EJ, Sweatman TW, Israel M, Lothstein L, Arsura M.

Mol Pharmacol. 2004 Apr;65(4):1038-47.

PMID:
15044634
15.
16.
17.

Novel extranuclear-targeted anthracyclines override the antiapoptotic functions of Bcl-2 and target protein kinase C pathways to induce apoptosis.

Barrett CM, Lewis FL, Roaten JB, Sweatman TW, Israel M, Cleveland JL, Lothstein L.

Mol Cancer Ther. 2002 May;1(7):469-81.

18.

Ciprofloxacin: a warning for clinicians.

Lothstein LM.

Conn Med. 2002 Jul;66(7):423-6. No abstract available.

PMID:
12181866
19.

Anthracycline drug targeting: cytoplasmic versus nuclear--a fork in the road.

Lothstein L, Israel M, Sweatman TW.

Drug Resist Updat. 2001 Jun;4(3):169-77. Review.

PMID:
11768330
21.

Molecular models of N-benzyladriamycin-14-valerate (AD 198) in complex with the phorbol ester-binding C1b domain of protein kinase C-delta.

Roaten JB, Kazanietz MG, Sweatman TW, Lothstein L, Israel M, Parrill AL.

J Med Chem. 2001 Mar 29;44(7):1028-34.

PMID:
11297449
22.

Catalytic inhibition of DNA topoisomerase II by N-benzyladriamycin (AD 288).

Lothstein L, Suttle DP, Roaten JB, Koseki Y, Israel M, Sweatman TW.

Biochem Pharmacol. 2000 Dec 1;60(11):1621-8.

PMID:
11077044
24.
25.

Risk management and treatment of sexual disinhibition in geriatric patients.

Lothstein LM, Fogg-Waberski J, Reynolds P.

Conn Med. 1997 Sep;61(9):609-18.

PMID:
9334516
26.

Circumvention of P-GP MDR as a function of anthracycline lipophilicity and charge.

Lampidis TJ, Kolonias D, Podona T, Israel M, Safa AR, Lothstein L, Savaraj N, Tapiero H, Priebe W.

Biochemistry. 1997 Mar 4;36(9):2679-85.

PMID:
9054575
27.
28.
29.
31.

Structural analysis of the mouse mdr1a (P-glycoprotein) promoter reveals the basis for differential transcript heterogeneity in multidrug-resistant J774.2 cells.

Hsu SI, Cohen D, Kirschner LS, Lothstein L, Hartstein M, Horwitz SB.

Mol Cell Biol. 1990 Jul;10(7):3596-606. Erratum in: Mol Cell Biol 1990 Nov;10(11):6101.

32.

Alternate overexpression of two P-glycoprotein [corrected] genes is associated with changes in multidrug resistance in a J774.2 cell line.

Lothstein L, Hsu SI, Horwitz SB, Greenberger LM.

J Biol Chem. 1989 Sep 25;264(27):16054-8. Erratum in: J Biol Chem 1990 Jan 25;265(3):1821.

34.

Video self-portraits: a novel approach to group psychotherapy with young adults.

Cox E, Lothstein LM.

Int J Group Psychother. 1989 Apr;39(2):237-53.

PMID:
2707935
35.

Twinship and alter ego selfobject transferences in group therapy with the elderly: a reanalysis of the pairing phenomenon.

Lothstein LM, Zimet G.

Int J Group Psychother. 1988 Jul;38(3):303-17. No abstract available.

PMID:
3182135
36.

Molecular/cytogenetic alterations accompanying the development of multidrug resistance in the J774.2 murine cell line.

Slovak ML, Lothstein L, Horwitz SB, Trent JM.

Leukemia. 1988 Jul;2(7):453-8.

PMID:
2899184
37.

Distinct P-glycoprotein precursors are overproduced in independently isolated drug-resistant cell lines.

Greenberger LM, Lothstein L, Williams SS, Horwitz SB.

Proc Natl Acad Sci U S A. 1988 Jun;85(11):3762-6.

38.
39.

Expression of phenotypic traits following modulation of colchicine resistance in J774.2 cells.

Lothstein L, Horwitz SB.

J Cell Physiol. 1986 May;127(2):253-60.

PMID:
3700481
40.

Taxol: mechanisms of action and resistance.

Horwitz SB, Lothstein L, Manfredi JJ, Mellado W, Parness J, Roy SN, Schiff PB, Sorbara L, Zeheb R.

Ann N Y Acad Sci. 1986;466:733-44. No abstract available.

PMID:
2873780
41.

Group therapy for latency age black males: unplanned interventions, setting, and racial transferences as catalysts for change.

Lothstein L.

Int J Group Psychother. 1985 Oct;35(4):603-23. No abstract available.

PMID:
4086129
42.

General organization of protein in HeLa 40S nuclear ribonucleoprotein particles.

Lothstein L, Arenstorf HP, Chung SY, Walker BW, Wooley JC, LeStourgeon WM.

J Cell Biol. 1985 May;100(5):1570-81.

43.

Female sexuality and feminine development: freud and his legacy.

Lothstein LM.

Adv Psychosom Med. 1985;12:57-70. No abstract available.

PMID:
4013881
44.

Transsexualism and physical deformity.

Lothstein LM, Billowitz A.

J Nerv Ment Dis. 1984 Oct;172(10):618-24.

PMID:
6481347
45.

Psychological testing with transsexuals: a 30-year review.

Lothstein LM.

J Pers Assess. 1984 Oct;48(5):500-7. Review.

PMID:
6389823
46.

Black female transsexuals and schizophrenia: a serendipitous finding?

Lothstein LM, Roback H.

Arch Sex Behav. 1984 Aug;13(4):371-86.

PMID:
6487080
47.

An MMPI subscale (Gd): to identify males with gender identity conflicts.

Althof SE, Lothstein LM, Jones P, Shen J.

J Pers Assess. 1983 Feb;47(1):42-9.

PMID:
6834232
48.

Amphetamine abuse and transsexualism.

Lothstein LM.

J Nerv Ment Dis. 1982 Sep;170(9):568-71.

PMID:
7108506
49.

Group therapy with gender-identity patients--a four-year study.

Keller AC, Althof SE, Lothstein LM.

Am J Psychother. 1982 Apr;36(2):223-8.

PMID:
7102842
50.

Sex reassignment surgery: historical, bioethical, and theoretical issues.

Lothstein LM.

Am J Psychiatry. 1982 Apr;139(4):417-26.

PMID:
7065286

Supplemental Content

Loading ...
Support Center